Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.63 |
| ▸ | MAPT | P10636 | 10/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL17673846 | 0.98 | ALDH1A1 (0.61) | ALDH1A1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL12943394 | 0.84 | MAPT (0.70) | ALDH1A1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL925443 | 0.82 | ALDH1A1 (0.49) | ALDH1A1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8083511 | 0.82 | MEN1 (0.54) | ALDH1A1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL28357165 | 0.81 | SMN1; SMN2 (0.55) | ALDH1A1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL330449 | 0.81 | MAPT (0.53) | ALDH1A1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL28127303 | 0.81 | MAPT (0.53) | ALDH1A1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL926042 | 0.80 | CYP3A4 (0.50) | ALDH1A1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL92933 | 0.79 | ALOX5 (0.66) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| Amiphenazole SCHEMBL139210 | 0.79 | ALDH1A1 (0.68) | ALDH1A1MAPTCYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4225737-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3741757-B1 | DIHYDROINDOLIZINONE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023061294-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 再鼎医药(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| CN-111630052-B | Dihydroindazinone derivatives | 第一三共株式会社 | 2023-04-18 | — | — | CN | disclosed |
| US-11530211-B2 | Dihydroindolizinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-20 | — | — | US | disclosed |
| US-20220339260-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2022-10-27 | — | — | US | disclosed |
| EP-3998107-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | Tokyo Institute of Technology (JP) | 2022-05-18 | — | — | EP | disclosed |
| EP-1956020-A2 | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity | SMITHKLINE BEECHAM PLC (GB) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007042767-A2 | A YELLOW DYE AND A PROCESS FOR INK JET PRINTING USING THE DYE | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| CN-1838953-A | Phosphatidylinositol 3-kinase (PI3) inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives for the treatment of inflammatory airway diseases | NOVARTIS AG (CH) | 2006-09-27 | — | — | CN | disclosed |
| CN-1838953-A | Phosphatidylinositol 3-kinase (PI3) inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives for the treatment of inflammatory airway diseases | NOVARTIS AG (CH) | 2006-09-27 | — | — | CN | disclosed |
| EP-0477373-B1 | METAL CHELATE COMPOUND AND OPTICAL RECORDING MEDIUM COMPRISING THE SAME | MITSUBISHI CHEM CORP (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5231173-A | DISAZO METAL CHELATE COMPOUNDS FOR OPTICAL RECORDING MEDIA | MITSUBISHI KASEI CORPORATION (JP) | 1993-07-27 | — | — | US | disclosed |
| EP-0477373-A1 | METAL CHELATE COMPOUND AND OPTICAL RECORDING MEDIUM COMPRISING THE SAME | Mitsubishi Chemical Corporation (JP) | 1992-04-01 | — | — | EP | disclosed |
| EP-0352581-A2 | Ethylene diaminmonoamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-31 | — | — | EP | disclosed |
| US-4233214-A | FOR POLYACRYLONITRILE AND ACID-MODIFIED POLYESTERS OR POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-11 | — | — | US | disclosed |
| US-4036826-A | Cationic azo dyestuffs with a hydroxyalkylated ammonium group | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530211-B2 | Dihydroindolizinone derivative | INSR, GPR119, IAPP | ALDH1A1 55/4885MAPT 4042/4885CYP1A2 1306/4885 |
| US-20220339260-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | IAPP, INSR, GPR119 | ALDH1A1 422/4885MAPT 3636/4885CYP1A2 977/4885 |
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A1 3668/4885MAPT 4872/4885CYP1A2 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.